MedTrace Logo

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

NCT01284478 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2012-10-04

No results posted yet for this study

Summary

The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery

Conditions

Interventions

DRUG

Dexamethasone Implant

Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Northern California Retina Vitreous Associates

    lead OTHER

Principal Investigators

  • Rahul Khurana, MD · Northern California Retina Vitreous Associates

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284478 on ClinicalTrials.gov